Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

This study will assess changes in complement factor B over a 69-week treatment period in a
patient population 55 and older with well-demarcated Geographic Atrophy secondary to Age
Related Macular Degeneration

Key Inclusion Criteria:

1. Must have given written informed consent and be able to comply with study requirements

2. Females must be non-pregnant and non-lactating, and either surgically sterile or
post-menopausal. Males must be surgically sterile or, if engaged in sexual relations
with a female of child bearing potential, the subject must be using an acceptable
contraceptive method from the time of signing the informed consent form until at least
a period of 13 weeks after the last dose of Study Drug (ISIS 696844 or placebo)

3. Well-demarcated Geographic Atrophy due to Age Related Macular Degeneration

Key Exclusion Criteria:

1. Clinically-significant abnormalities in medical history

2. Diagnosis of primary or secondary immunodeficiencies of B lymphocyte function,
splenectomy, glomerulonephritis or history of recurrent meningococcal disease

3. Diabetes mellitus or thyroid disease unless well controlled for a period of at least 3
months

4. Clinically-significant abnormalities in screening laboratory values

5. Unwillingness to be administered, or history of a serious reaction to protocol
required vaccines

6. Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C
or chronic hepatitis B

7. History or presence of a disease other than AMD in study eye